Tuscany, Italy

Logidex srlVia Galileo Galilei 17A 52041 Pieve al Toppo Civitella in Val di ChianaArezzo, Italyt/f 0039 0575 478704logidex@logidex.it

FIBRINOSILfor the treatment of inflammations

BROMELAINDEVIL’S CLAW

Logidex srlVia Montemagno 3910132 - Torino (Italy)t +39 011 19234680f +39 011 19234681logidex@logidex.it

Torino, Italy

Logidex srlVia Galileo Galilei 17A 52041 Pieve al ToppoArezzo, Italylogidex@logidex.it

for the treatment of inflammationsF IBRINOSIL

EFF ICACY

ANTIPHLO G IST IC ANT I OEDEMA

INF LAM MATIO N

ANALGES IC

HEAT REDNESS SWELL ING PA IN REDUCED FUNCT IO NAL CAPAC IT Y

Serrapeptase is a proteolytic enzyme presenting anti-inflammatory, anti-aedematigenous, protelyitic and trobolythic effects. Most of its effects are related to its anti bradykinin activity.

BRADYKININ

VASODILATIONINCREASE OF

CAPILLARY LEAK

OEDEMA

SERRAPEPTASE

Serrapeptase is present in any oedematigenous process of any nature and in particular in those of post traumatic and post surgery origin. The compound has been tested for the treatment of VOD and venous ulcers. This product is also associated to antibiotic treatment for abscess and in any case where the infection is encapsulated in a reactive fibrotic tissue.

Composition: Bromelain, Serrapeptase, Devil’s Claw

Logidex srlVia Galileo Galilei 17A 52041 Pieve al ToppoArezzo, Italylogidex@logidex.it

for the treatment of inflammationsF IBRINOSIL

ACUTE PHASE TISSUE REPAIR PHASE

INFLAMMATORY PROCESS

ANTI-INFLAMMATORY(PROSTAGLANDINS PGE1, PG2, PG3)

PRO-INFLAMMATORY(PROSTAGLANDINS PGE2)

Harpagophytum Procumbens (Devil’s Claw) is extracted from the roots of the plants belonging to the Pedaliaceae family: it has a well recognized analgesic and anti-inflammatory action.

ARPAGOPHYTUN PROCUMBENS

Bromelain activates the release of the anti-inflammatory prostaglandins that have a fundamental role in the tissue repair against the family of the pro-inflammatory prostaglandins. This mechanism decreases the need for use of NSAIDs and it improves their performance.

Bromelain appears to increase the production of plasmin, which also has a fibrinolytic effect and therefore reduces the formation of localized oedema.

Bromelain reduces the formation of kininogen and therefore of kinin, vasoactive substances, cause pain and oedema.

CH3

CH3

CH3

CH3

HO

O

H

HH

H OH

F

O

OO

BROMELAIN

Logidex srlVia Galileo Galilei 17A 52041 Pieve al ToppoArezzo, Italialogidex@logidex.it

per il trattamento delle infiammazioni delle mucose oraliOROXIL

REFERENCES

GIOVANNI N. BERTA, Z. YANG, M. ARGENZIANO, P. SALAM-ONE, E. PIRRO, A. E. SPRIO, F. DI SCIPIO, M. E. CARERE, E. QUAGLINO, F. CAVALLO, R. CAVALLI. 2-HYDROXYPRO-PYL- -CYCLODEXTRIN COMPLEXATION IMPROVES ORAL BIO-AVAILABILITY OF RESVERATROL.

LETTIERI BARBATO D, TATULLI G, AQUILANO K, CIRIOLO MR 2014. INHIBITION OF AGE-RELATED CYTOKINES PRO-DUCTION BY ATGL: A MECHANISM LINKED TO THE AN-TI-INFLAMMATORY EFFECT OF RESVERATROL. MEDIATORS INFLAMM 2014: 917698.

THOMPSON AM, MARTIN KA, RZUCIDLO EM 2014. RES-VERATROL INDUCES VASCULAR SMOOTH MUSCLE CELL DIFFERENTIATION THROUGH STIMULATION OF SIRT1 AND AMPK. PLOS ONE 9(1):E85495.

ANSARI KA, VAVIA PR, TROTTA F, CAVALLI R 2011. CYCLO-DEXTRIN-BASED NANOSPNGES FOR DELIVERY OF RESVERATROL: IN VITRO CHARACTERISATION, STABILITY, CYTOTOXICITY AND PERMEATION STUDY. AAPS PHARMSCITECH 12(1):279-286.

LU Z, CHENG B, HU Y, ZHANG Y, ZOU G 2009. COMPLEX-

ATION OF RESVERATROL WITH CYCLODEXTRIN: SOLUBILITY AND ANTIOXIDANT ACTIVITY. FOOD CHEMISTRY 113(1):17-20.

ALARCÒN ET AL. RESVERATROL AS AN ANTI-INFLAMMATORY ADN ANTI-AGING AGENT:MECHANISMS AND CLINICAL IMPLICA-TIONS. MOL. NUTR. RES. 2005, 49, 405-430.

T. WALLE BIOAVAILABILITY OF RESVERATROL. ANN. N.Y. ACAD. SCI. ISSN 0077-8923

C. ALARCÒN DE LA LASTRA, I. VILLEGAS. RESVERATROL AS AN ANTIOXIDANT AND PRO-OXIDANT AGENT: MECHANISMS AND CLINICAL IMPLICATION. BIOCHEMICAL SOCIETY TRANS-ACTIONS (2007) VOL. 35, PART 5.

N. SUMMERLIN, E. SOO, S. THAKUR, Z. QU ED AL., RESVER-ATROL NANOFORMULATIONS: CHALLENGES AND OPPORTU-NITIES. INTERNATIONAL JOURNAL OF PHARMACEUTICS 479 (2015) 282-290.

S. SHARAN, O.F. IWUCHUKWU, D. J. CANNEY ET AL., IN VI-VO-FORMED VERSUS PREFORMED METABOLITE KINETICS OF TRANS-RESVERATROL-3-SULFATE AND TRANS-RESVERA-TROL-3-GLUCURONIDE. DRUG METABOLISM AND DISPOSITION 40:1993-2001, 2012

POSOLOGY: 1 of 20 ml 1-2 times per day.

ACTIVE INGREDIENTS:*

-Cyclodextrin

INDICATED FOR THE TREATMENT OF:

-

-mo-radiotherapy of the oral cavity. * One 200 ml sample contains.

Logidex srlVia Galileo Galilei 17A 52041 Pieve al ToppoArezzo, Italylogidex@logidex.it

for the treatment of inflammationsF IBRINOSIL

REFERENCES

FITZHUGHN DJ, SHAN S, DEWHIRST MW ET AL. (2008). BROMELAIN TREATMENT DECREASES NEUTROPHIL MIGRATION TO SITES OF INFLAMMATIO.

CLIN IMMUNOL 128:66-74.

ESCH PM, GERNGROSS H, FABIAN A. REDUCTION OF POST OPERATIVE SWELLING. OBJECTIVE MEASURAMENT OF SWELL-ING OF THE UPPER ANKLE JOINT IN TREATMENT WITH SERRA-PEPTASE: APROSPECTIVE STUDY. FORTSCHR MED. 1989 FEB 10; 107(4):67-8, 71-2. GERMAN

SOHANN K, ESCHMANN K, MEISNER P. NO CLINICAL EV-IDENCE FOR AN ENHANCED BLEEDING TENDENCY DUE TO PERIOPERATIVE TREATMENT WITH BROMELAIN. SPORTVERLEZ SPORTSCHADEN 2011 JUN; 25(2):108-13

INCHINGOLO F, TATULLO M, MARRELLI M, INCHINGOLO AM, PICCIARELLO V, INCHINGOLO AD, DIPALMA G, VERMESAN D, CAGIANO R. CLINICAL TRIAL WITH BROMELAIN IN THIRD MOLAR EXODONTIA. EUR REV MED PHARMACOL SCI. 2010 SEP; 14(9): 711-4.

KLEIN G, KULICH W ET AL. REDUCING PAIN BY ORAL ENZYME THERAPY IN RHEUMATIC DISEASE. WIEN MED WOCHENSCHR

1999; 149 (21-22): 577-80.

SUNNINO G, GIGOLA P, ET AL. COMBINATION THERAPY IN-CLUDING SERRATIOPEPTIDASE IMPROVES OUTCOMES OF ME-CHANICAL ANTIOBIOTIC

TREATNENT OF PERI-IMPLANTITIS. INT J IMMUNOPATHOL PHARMACOL 2013 JUL-SEPT; 26(3): 825-31

NAKAMURA S, HASHIMOTO Y ET AL, EFFECT OF THE PRO-TEOLYTIC ENZYME SERRAPEPTIDASE IN PATIENTS WITH CHRON-IC AIRWAY DISEASE.

RESPIROLOGY 2003 SEPT; 8(3): 316-20

SELAN L, BERLUTTI F ET AL, PROTEOLYTIC ENZYMES: A NEW TRATMENT STRATEGY FOR PROSTHETIC INFECTIONS?ANTIMI-CROBIC AGENTS CHEMIOTHER

1993 DEC 37(12) 26-18-21

MAZZONE A, CATALANI M ET AL EVALUATION OF SERRATIO-PEPTIDASE IN ACUTE OR CHRONIC INFLAMMATION IN OTORHI-NOLARYNCOLOGY PATHOLOGY: A MULTICENTRE DOUBLE-BLIND, RANDOMIZED TRIAL VERSUS PLACEBO. J INT MED RES 1990 SEPT-OCT; 18(5): 379-88

ACTIVE INGREDIENTS:

POSOLOGY:

INDICATED FOR THE TREATMENT OF:

Logidex srlVia Galileo Galilei 17A 52041 Pieve al ToppoArezzo, Italialogidex@logidex.it

per il trattamento delle infiammazioni delle mucose oraliOROXIL

REFERENCES

GIOVANNI N. BERTA, Z. YANG, M. ARGENZIANO, P. SALAM-ONE, E. PIRRO, A. E. SPRIO, F. DI SCIPIO, M. E. CARERE, E. QUAGLINO, F. CAVALLO, R. CAVALLI. 2-HYDROXYPRO-PYL- -CYCLODEXTRIN COMPLEXATION IMPROVES ORAL BIO-AVAILABILITY OF RESVERATROL.

LETTIERI BARBATO D, TATULLI G, AQUILANO K, CIRIOLO MR 2014. INHIBITION OF AGE-RELATED CYTOKINES PRO-DUCTION BY ATGL: A MECHANISM LINKED TO THE AN-TI-INFLAMMATORY EFFECT OF RESVERATROL. MEDIATORS INFLAMM 2014: 917698.

THOMPSON AM, MARTIN KA, RZUCIDLO EM 2014. RES-VERATROL INDUCES VASCULAR SMOOTH MUSCLE CELL DIFFERENTIATION THROUGH STIMULATION OF SIRT1 AND AMPK. PLOS ONE 9(1):E85495.

ANSARI KA, VAVIA PR, TROTTA F, CAVALLI R 2011. CYCLO-DEXTRIN-BASED NANOSPNGES FOR DELIVERY OF RESVERATROL: IN VITRO CHARACTERISATION, STABILITY, CYTOTOXICITY AND PERMEATION STUDY. AAPS PHARMSCITECH 12(1):279-286.

LU Z, CHENG B, HU Y, ZHANG Y, ZOU G 2009. COMPLEX-

ATION OF RESVERATROL WITH CYCLODEXTRIN: SOLUBILITY AND ANTIOXIDANT ACTIVITY. FOOD CHEMISTRY 113(1):17-20.

ALARCÒN ET AL. RESVERATROL AS AN ANTI-INFLAMMATORY ADN ANTI-AGING AGENT:MECHANISMS AND CLINICAL IMPLICA-TIONS. MOL. NUTR. RES. 2005, 49, 405-430.

T. WALLE BIOAVAILABILITY OF RESVERATROL. ANN. N.Y. ACAD. SCI. ISSN 0077-8923

C. ALARCÒN DE LA LASTRA, I. VILLEGAS. RESVERATROL AS AN ANTIOXIDANT AND PRO-OXIDANT AGENT: MECHANISMS AND CLINICAL IMPLICATION. BIOCHEMICAL SOCIETY TRANS-ACTIONS (2007) VOL. 35, PART 5.

N. SUMMERLIN, E. SOO, S. THAKUR, Z. QU ED AL., RESVER-ATROL NANOFORMULATIONS: CHALLENGES AND OPPORTU-NITIES. INTERNATIONAL JOURNAL OF PHARMACEUTICS 479 (2015) 282-290.

S. SHARAN, O.F. IWUCHUKWU, D. J. CANNEY ET AL., IN VI-VO-FORMED VERSUS PREFORMED METABOLITE KINETICS OF TRANS-RESVERATROL-3-SULFATE AND TRANS-RESVERA-TROL-3-GLUCURONIDE. DRUG METABOLISM AND DISPOSITION 40:1993-2001, 2012

POSOLOGY: 1 of 20 ml 1-2 times per day.

ACTIVE INGREDIENTS:*

-Cyclodextrin

INDICATED FOR THE TREATMENT OF:

-

-mo-radiotherapy of the oral cavity. * One 200 ml sample contains.